Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Medivir AB    MVIR B   SE0000273294


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Medivir : Phase II COSMOS study results published in The Lancet on World Hepatitis Day

share with twitter share with LinkedIn share with facebook
share via e-mail
07/28/2014 | 05:24am EDT

Press release as PDF

Phase II COSMOS study results published in The Lancet on World Hepatitis Day

Stockholm, Sweden - Medivir AB (OMX: MVIR) announces that results from the phase II COSMOS clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The study included patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin.

According to results from the study, the all-oral, interferon-free treatment regimen with simeprevir and sofosbuvir resulted in consistent SVR12 rates regardless of degree of fibrosis, and was an effective and well-tolerated therapeutic regimen in both treatment-naïve and prior null-responder patients.

"The Lancet publication of the COSMOS data on World Hepatitis Day gives further recognition to these revolutionizing treatment results. I hope that this will contribute to helping more patients around the world to get cured." says Henrik Krook, EVP Commercial, Medivir AB.

Based on the findings from the COSMOS study, our partner Janssen in April initiated the phase III studies OPTIMIST-1 and OPTIMIST-2 examining the safety and efficacy of simeprevir and sofosbuvir without interferon or ribavirin for the treatment of chronic genotype 1 hepatitis C infection.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

About Simeprevir (Olysio®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. Simeprevir was approved in September 2013 in Japan, in November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014 in Mexico and Australia.

In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it is anticipated that simeprevir will be available across a number of European Union countries in conjunction with reimbursement, in the second half of 2014. Simeprevir (Olysio) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union.

About Medivir
Medivir is an emerging and profitable research-based pharmaceutical company with an established marketing and sales organisation in the Nordics with a broad portfolio of prescription pharmaceuticals. Medivir receives royalty from Johnson & Johnson global sales of the hepatitis C pharmaceutical Olysio. In addition, revenues for sales of Olysio in the Nordic region is generated through the companies own sales and marketing organisation.  

Medivir's research and development portfolio of pharmaceuticals is based on the company's expertise in polymerase and protease drug targets for different disease areas. The company's current research and development is focused on infectious diseases, bone related disorders, neuropathic pain and oncology.

Medivir is listed on the Nasdaq OMX Mid-Cap list.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MEDIVIR AB
06/13MEDIVIR : Selective effect signal on liver cancer tissue in phase Ia study with ..
06/04MEDIVIR : to present at the 2019 BIO International Convention
06/03MEDIVIR : New data from the phase I study of birinapant in combination with Keyt..
05/27MEDIVIR : to present at the Redeye Pre-ASCO Seminar on May 28
05/16MEDIVIR : New data from the phase I study of birinapant in combination with Keyt..
05/13MEDIVIR : Positive data from the remetinostat phase II study in basal cell carci..
05/09MEDIVIR : Resolutions at the Annual General Meeting in Medivir on 9 May 2019
05/07MEDIVIR : Data from the remetinostat phase II study in basal cell carcinoma pati..
05/06MEDIVIR : Safety and efficacy data from the MIV-711 phase II open label extensio..
05/03MEDIVIR : Interim report, january - march 2019
More news
Financials (SEK)
Sales 2019 9,70 M
EBIT 2019 -217 M
Net income 2019 -217 M
Finance 2019 81,4 M
Yield 2019 -
P/E ratio 2019 -2,85x
P/E ratio 2020 -3,73x
EV / Sales2019 54,8x
EV / Sales2020 80,8x
Capitalization 613 M
Duration : Period :
Medivir AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIVIR AB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 38,10  SEK
Last Close Price 25,25  SEK
Spread / Highest target 114%
Spread / Average Target 50,9%
Spread / Lowest Target 14,9%
EPS Revisions
Uli Alf Hacksell President, Chief Executive Officer & Director
Anna Yvonne Monica Malm Bernsten Chairman
Richard Bethell Chief Scientific Officer
Daniel Eriksson Chief Information Officer
Anders R. Hallberg Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB14.94%11 908